A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

• Status: Active, not recruiting
• Trial end date: 2025-11-21
• Target enrollment: 0
• Participant gender: All

Summary

A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Criteria

Inclusion Criteria:

• Signed ICF prior to any study-mandated procedure;

• Subject completed the 6-month, double-blind treatment period in study ID 069A301

• Woman of childbearing potential only if agreement 1) to follow a specified contraception scheme, 2) to undertake monthly urine pregnancy tests , 3) not to donate ova.

• Fertile male only if agreement 1) to use a condom, 2) to not father a child, 3) not to donate sperm.

Exclusion Criteria:

• Pregnant / planning to be become pregnant or lactating subject;

• Subject considered to be at high risk of developing clinical signs of organ involvement within the time period of the study, as per investigator judgment;

• Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results as per investigator judgment.

In addition, the subject must not be enrolled in study ID-069A302 if at any time during study ID-069A301, one of the following criteria was met:

• Subject's eGFR per the Chronic Kidney Disease Epidemiology Collaboration creatinine equation < 15 mL/min/1.73 m2;

• Subject experienced an event of acute kidney injury Common Terminology Criteria for Adverse Event (CTCAE) grade 2 or above;

• Subject experienced an event of stroke CTCAE grade 3 or above;

• Subject experienced an event of heart failure leading to in-patient hospitalization or prolongation of ongoing hospitalization.